1,2,3-Propanetricarboxylicacid, 2-hydroxy-, gallium salt (1:1)

Suppliers

Names

[ Name ]:
1,2,3-Propanetricarboxylicacid, 2-hydroxy-, gallium salt (1:1)

[Synonym ]:
GALLIUMCITRATEANDCOMPOUNDS
Citric acid,gallium salt (1:1)
gallium citrate
2-Hydroxy-1,2,3-propanetricarboxylic acid gallium salt

Chemical & Physical Properties

[ Boiling Point ]:
309.6ºC at 760mmHg

[ Molecular Formula ]:
C₆H₁₁GaO₇

[ Molecular Weight ]:
264.87000

[ Flash Point ]:
155.2ºC

[ Exact Mass ]:
263.97600

[ PSA ]:
132.13000

[ Vapour Pressure ]:
5.73E-05mmHg at 25°C

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: GE7675000

CAS REGISTRY NUMBER :: 27905-02-8

LAST UPDATED :: 199106

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C6-H5-O7.Ga

MOLECULAR WEIGHT :: 258.83

WISWESSER LINE NOTATION :: QV1XQVQ1VQ &-GA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2227 mg/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 37 mg/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 55500 ug/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 167 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 74 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - domestic

DOSE/DURATION :: 37 mg/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - domestic

DOSE/DURATION :: 56 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 98,409,1950

Related Compounds

Bis(4-chlorophenyl)(5,5,6,6,7,7,8,8,8-nonafluoro-1-iodooctan-3-yl)phosphine oxide
(S)-1-(3-Chloro-4-(trifluoromethyl)phenyl)-2-methoxyethan-1-amine
6-Butoxy-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione
S-(4-Methoxyphenyl) 2-methylprop-2-enethioate
5-Bromo-4-chloro-7-methylindoline-2,3-dione
4,4'-(((((4,4'-((Ethane-1,2-diylbis(oxy))bis(carbonyl))bis(benzoyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(carbonyl))dibenzoic acid
2-(4,4-Dimethyl-3-phenyl-4,5-dihydroisoxazol-5-yl)acetamide
(2S,5S)-1-(tert-Butyl)-2,5-dimethylphospholan-1-ium tetrafluoroborate
Rel-(3aR,5R,7aR)-octahydro-1H-isoindol-5-ol hydrochloride
(2R,4R,5R,6S)-5-hydroxy-4-(oxan-2-yloxymethyl)-3,7-dioxa-1,9-diazatricyclo[6.4.0.02,6]dodeca-8,11-dien-10-one

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.